Management of XXXX .

@entity1665 @entity1 @entity12769 @entity585
@entity1665 is by far the most common cause of hair loss. It affects approximately 50% of @entity1 by the age of 50 and 20 to 53% of @entity1 by the age 50. Although it is a medically benign condition, it is a significant psychosocial issue for many @entity1 . Various different treatment options are now available for @entity1665 . The best treatment option for @entity1 with @entity1665 @entity12769 stage I and II is minoxidil 5% solution. If it is not effective after 1 year, antiandrogens can be tried, but there are no large studies showing their efficacy and they have considerable adverse effects. Also, for @entity1 with @entity1665 that is unresponsive to treatment or with @entity12769 stage III, hair transplantation can be offered if the occipital donor area is sufficient. For @entity1 , we always offer minoxidil or @entity585 therapy and leave the choice of therapy to the @entity1 . Some @entity1 may prefer a systemic agent, whereas others may favor a topical agent. If the condition is not stabilized after 1 year or if the @entity1 wants greater hair density, hair transplantation can be discussed. There have been tremendous advances in the treatment of hair loss in recent years and the future is very encouraging. As our knowledge of @entity1665 pathophysiology increases, novel targeted treatments will potentially be developed.
